𝔖 Bobbio Scriptorium

✦ LIBER ✦

Treatment-related deaths in small cell lung cancer trials: Can patients at risk be identified?

Book ID: 123401393
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 137 KB
Volume: 12
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(95)96458-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment-related deaths in small cell l

Treatment-related deaths in small cell lung cancer (SCLC) trials: Can patients at risk be identified?

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Risk Of Death At One Year In Patients Wi

Risk Of Death At One Year In Patients With Non-Small Cell Lung Cancer (Nsclc) Treated With Cisplatin Regimens: An Indirect Comparison Meta-Analysis Based On Renal Eligibility Criteria

✍ Bellows, B.K.; Dahal, A.; Agarwal, N. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

P-327 Can performance status (PS) be det

P-327 Can performance status (PS) be determined accurately bypatients? Results of a prospective trial evaluating ECOG and Karnofsky PS as well as patient-rated PS in non-small cell lung cancer (NSCLC)

✍ Gralla, R.; Hollen, P.; Kuruvilla, P.; Meharchand, J.; Solow, H.; Leighl, N.; Ch 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 268 KB

O-232 Can survival differences be found

O-232 Can survival differences be found among cisplatin, carboplatin, and non-platinum regimens? Results of a comprehensive review of chemotherapy in advanced non-small-cell lung cancer (NSCLC) randomized trials including 12181 patients from 1992–2002

✍ Raftopoulos, Harry; Gralla, Richard J.; Nelli, Fabrizzio; D'Auria, Giulliana; Br 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

A randomized trial in 516 patients with

A randomized trial in 516 patients with small cell lung cancer comparing 1) two durations of initial chemotherapy (1.Ct.) and 2) further therapy (rel. Ct.) or symptomatic treatment alone (sympt) at the time of disease progression

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 89 KB

P-848 Prevention of chemotherapy-induced

P-848 Prevention of chemotherapy-induced febrile neutropenia (FN) by the addition of granulocyte-colony stimulating factor (G-CSF) to antibiotics in small cell lung cancer (SCLC) patients at risk of FN: A prospective economic evaluation along a Dutch randomised phase III trial

✍ Timmer-Bonte, J.; Adang, E.; de Boo, T.; Tjan-Heijnen, V. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 289 KB